Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Mylan Head Of Biologics Chrys Kokino On Fulphila Launch And US Biosimilars

Oct 08 2018

• By Jessica Merrill

Chrys Kokino — Mylan Head of Biologics Chrys Kokino

Related Content

From Interchangeability To Exclusivity: US FDA Looks For Ways To Make Biologics Market More Competitive

Sep 07 2018

Mylan Poised To Launch Its First US Biosimilar, With A Stacked Pipeline Behind It

Apr 12 2018

Mylan To Explore Strategic Options, Claiming Investors Have Failed To Appreciate The Value

Aug 08 2018

Momenta Is Exiting Biosimilars; Is That A Bellwether For Biosimilar Sentiment?

Oct 02 2018

Mylan Is First To Clear US Neulasta Biosimilar Hurdle; At-Risk Launch May Not Be Risky

Jun 05 2018

Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown

Jul 12 2018

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts

Sep 20 2017

Related Companies

Viatris Inc.

Amgen, Inc.

Pfizer Inc.

Merck & Co., Inc.

Johnson & Johnson

Teva Pharmaceutical Industries Ltd.

Momenta Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb Company

Roche Holding AG

AbbVie Inc.

GSK plc

Sanofi

Additional Topics

United States Biosimilars Strategy Launches Companies Business Strategies Market Intelligence Pricing Strategies Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window